OR WAIT null SECS
February 15, 2017
With a total of 2,145 products currently in development, the immunology market is experiencing a high level of investment compared to many other therapy areas, according to GBI Research. The company’s latest report states that, within immunology, the largest pipeline segments are general treatment of inflammation, with 510 products currently in development, and rheumatoid arthritis, with 488. Additionally, psoriasis, inflammatory bowel disease, transplantation, ulcerative colitis, lupus, and allergies are all substantial indications with over 100 pipeline products in development. In terms of the market landscape, a total of 497 licensing deals and 433 co-development deals in the immunology therapy area were identified as having been completed between 2006 and 2016, with a combined aggregate value of $46 billion. See the report here.